Evaluation of novel particles as pulmonary delivery systems for insulin in rats

AAPS Journal

Volumn 5, Issue 2, 2003, Pages

  Garcia Contreras, Lucila ^a   Morçöl, Tülin ^b   Bell, Steve J D ^b   Hickey, Anthony J ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b BioSante Pharmaceuticals Inc   (United States)

Author keywords

CAP PEG particles; Insulin; Pharmacodynamics; Pharmacokinetics; Pulmonary delivery

Indexed keywords

EID: 55449116527     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Garcia-Contreras L, Sarubbi D, Flanders E, et al. Immediate and short-term cellular and biochemical responses to pulmonary single-dose studies of insulin and H-MAP. Pharm Res. 2001; 18(12): 1685-1693.
2. Suarez S, García-Contreras L, Sarubbi D, et al. Facilitation of pulmonary insulin absorption by H-MAP: pharmacokinetics and pharmacodynamics in rats. Pharm Res. 2001;18(12):1677-1684.
3. Pohl R, Muggenburg B A, Wilson B, Woods RJ, Burrell BE, Steiner SS. A dog model as predictor of the temporal properties of pulmonary technosphere/insulin in humans. In: Dalby RN, Byron PR, Peart J, Fair SJ, eds. Respiratory Drug Delivery VII. Raleigh, NC: Davis Horwood International Publishing; 2000; 463-465.
4. Brown LR, Rashba-Step J, Scott T, et al. Pulmonary delivery of novel insulin microspheres. In: Dalby RN, Byron PR, Peart J, Fair SJ, eds. Respiratory Drug Delivery VIII. Raleigh, NC: Davis Horwood International Publishing; 2002; 431-433.
5. Blair J, Coghlan D, Langner E, Jansen M, Askey-Sarvar A. Sustained delivery of insulin via the lung using Solidose technology. In: Dalby RN, Byron PR, Peart J, Fair SJ, eds. Respiratory Drug Delivery VIII. Raleigh, NC: Davis Horwood International Publishing; 2002; 411-413.
6. Edwards DE, Ben-Jebria A, Langer R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol. 1997;84(2):379-385.
7. Edwards DE, Hanes J, Caponetti G, et al. Large porous particles for pulmonary drug delivery. Science 1997;276:1868-1871.
8. Vanbever R, Mintzes JD, Wang J, et al. Formulation and physical characterization of large porous particles for inhalation. Pharm Res. 1999;16(11):1735-1742.
9. Morcol T, Nagappan P, He Q, Bell SJD Utilizing calcium phosphate particles as drug delivery vehichles for therapeutic proteins, IIR-USA, ed. IIR-USA 1st Annual Protein and Peptide Formulation Strategies, August 19-21, 2002;9-15.
10. Yeh MK, Jenkins PG, Davis SS, Coombes AGA. Improving the delivery capacity of microparticle system using blends of poly(DL-lactide co-glycolide) and poly(ethylene glycol). J Control Release 1995;37:1-9.
11. Gehrke SH, Uhden LH, McBride JF. Enhanced loading and activity retention of bioactive proteins in hyrdogel delivery systems. J Control Release 1998;55:21-33.
12. Rocci ML, Jusko WL. LAGRAN program for area and moments in pharmacokinetics. Comp Prog Biomed. 1983;16:203-211.
13. Garcia-Contreras L, Morcol T, Bell SJD, Hickey AJ. Evaluation of novel calcium phosphate particles as pulmonary delivery systems for insulin in rats. AAPS PharmSci (Suppl) 2001;3(3).
14. Cefalu WT, Balagtas CC, Landschultz WH, Gelfand RA. Sustained efficacy and pulmonary safety of inhaled insulin during 2 years of outpatient therapy. Diabetes 2000;49(Suppl 1):A406.
15. He Q, Mitchell AR, Johnson SL, Wagner-Bartak C, Morcol T, Bell SJD. Calcium phosphate nanoparticle adjuvant. Clin Diagnos Lab Immunol. 2000;7:899-903.
16. Gonda I. Drugs administered directly into the respiratory tract: modeling of the duration of effective drug levels. J Pharm Sei 1988;77(4):340-346.
17. Patton JS, Bukar J, Nagarajan S. Inhaled insulin. Adv Drug Deliv Rev 1999;35:235-247.
18. Brunner GA, Baient B, Ellmerer M, et al. Dose-response relation of liquid aerosol inhaled insulin in type I diabetic patients. Diabetologia 2001;44:305-308.
19. Huffman A, Ziv E. Pharmacokinetic considerations of new insulin formulations and routes of administration. Clin Pharmacokinet. 1997;33(4):285-301.
20. Rave K, Heise T, Pfutzner A, Steiner SS, Heinemann L. Assesment of dose-reponse characteristics for a new pulmonary insulin formulation and an inhaler. Exp Clin Endocrinol Diabetes 2000;108(Suppl. 1):S161.
21. Steiner SS, Rave K, Heise T, et al. Pharmacokinetic properties and bioavailability of inhaled dry powder TechnosphereTM/Insulin. Exp Clin Endocrinol Diabetes 2000;108(Suppl. 1):S161.
22. Steiner SS, Pfutzner A, Wilson B, Harzer O, Heinemann L, Rave K. TechnosphereTM / Insulin: proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes 2002; 110:17-21.
23. Okumura K, Iwakawa S, Yoshida T, Seki T, Komada F. Intratracheal delivery of insulin absorption from solution and aerosol by rat lung. Int J Pharm. 1992;88:63-73.
24. Komada F, Iwakawa S, Yamamoto N, Sakakibara H, Okumura K. Intratracheal delivery of peptide and protein agents: absorption from solution and dry powder by rat lungs. J Pharm Sei 1994;83:863-867.
25. Kawashima Y, Yamamoto H, Takeguchi H, Fujioka S, Hino T. Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J Control Release. 1999;62:279-287.
26. Morimoto K, Metsugi K, Katsumata H, Iwanaga K, Kakemi M. Effects of low viscosity sodium hyaluronate preparation on the pulmonary absorption of rh-insulin in rats. Drug Dev Ind Pharm. 2001;27(4):365-371.
27. Scott T, Sullivan A, Proos R, et al. Novel technology for fabrication of therapeutic microspheres for pulmonary delivery. In: Dalby RN, Byron PR, Peart J, Fair SJ, eds. Respiratory Drug Delivery VIII. Raleigh, NC: Davis Horwood International Publishing; 2002; 435-437.